Bernstein Maintains Outperform on Insulet, Lowers Price Target to $200

Benzinga Newsdesk www.benzinga.com Negative 95.4%

Neg 95.4% Neu 0% Pos 0%

Bernstein analyst Lee Hambright maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $330 to $200.